

**FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)**

*Cardiovascular and Renal Drugs Advisory Committee  
Meeting  
June 16, 2005*

***Participant List***

**Consultants**

**(Voting)**

**Jonathan Sackner-Bernstein, M.D.**

Associate Chief of Cardiology  
Director of the Heart Failure Program  
St. Luke's-Roosevelt Hospital Center  
1000 10th Ave  
New York, NY 10025

**Thomas Fleming, Ph.D.**

Professor and Chairman  
Department of Biostatistics  
University of Washington  
1705 Pacific Ave., NE  
Seattle, Washington 98195

**Mr. Robert J. Samuels**

Patient Representative  
8509 Woodwick Court  
Tampa, FL 33615

**Vivian Ota Wang, Ph.D.**

Program Director  
Ethical, Legal, and Social Implications  
Program  
National Human Genome Research Institute  
National Institutes of Health  
5635 Fishers Lane, Suite 4076, MSC 9305  
Bethesda, Maryland 20892-9305

**Consultants**

**(Non-Voting)**

**Charles H. McLeskey, M.D.**

**(Industry Representative)**

Senior Development, Clinical Development  
Abbott Laboratories  
Hospital Products Division  
200 Abbott Park Road  
Abbott Park, Illinois 60604

**FDA Participants**

**Norman Stockbridge, M.D.**

Acting Director  
Division of Cardiovascular and  
Renal Drug Products  
FDA/CDER  
1451 Rockville Pike  
Rockville, MD 20852

**Robert Temple, M.D.**

Director  
Office of Drug Evaluation I (ODEI)  
FDA/CDER  
5515 Security Lane  
Rockville, MD 20852